“Maintains a 'BUY' rating on Park Medi World, revising its June-27 price target up by 7% to ₹375 from ₹350, based on 21x June-28E EV/EBITDA. The brokerage highlights strong Q1FY27 performance with 19%/20% yoy revenue/EBITDA growth, agile acquisition playbook, focus on profitability, and ramp-up of new units. Expects 25% revenue CAGR over FY26-29E with ~1.8k bed additions over the next 18 months.”